Paul Tudor Jones Beam Therapeutics Inc. Transaction History

Tudor Investment Corp Et Al

$25.1 Billion
Q4 2024

A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 16,575 shares of BEAM stock, worth $436,585. This represents 0.0% of its overall portfolio holdings.

Number of Shares

16,575

Previous 32,817 49.49%

Holding current value

$436,585

Previous $804,000 48.88%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$21.55 - $30.35 $350,015 - $492,944	-16,242 Reduced 49.49%	16,575 $411,000
Q3 2024 Nov 14, 2024	SELL	$22.57 - $33.14 $365,746 - $537,033	-16,205 Reduced 33.06%	32,817 $804,000
Q2 2024 Aug 14, 2024	BUY	$21.22 - $32.66 $24,975 - $38,440	1,177 Added 2.46%	49,022 $1.15 Million
Q1 2024 May 15, 2024	BUY	$23.46 - $45.07 $1.12 Million - $2.16 Million	47,845 New	47,845 $1.58 Million
Q2 2023 Aug 14, 2023	BUY	$29.32 - $35.99 $199,991 - $245,487	6,821 New	6,821 $217,000
Q3 2022 Nov 14, 2022	BUY	$39.79 - $70.31 $1.62 Million - $2.87 Million	40,839 New	40,839 $1.95 Million
Q2 2022 Aug 15, 2022	SELL	$29.86 - $62.36 $224,487 - $468,822	-7,518 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$53.73 - $82.16 $403,942 - $617,678	7,518 New	7,518 $431,000
Q4 2021 Feb 14, 2022	SELL	$68.02 - $99.06 $3.2 Million - $4.65 Million	-46,974 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$84.37 - $133.6 $3.52 Million - $5.57 Million	41,728 Added 795.43%	46,974 $4.09 Million
Q2 2021 Aug 16, 2021	BUY	$64.12 - $128.71 $336,373 - $675,212	5,246 New	5,246 $675,000

Others Institutions Holding BEAM

# of Institutions

253

Shares Held

78.6M

Call Options Held

304K

Put Options Held

142K

View Full List

About Beam Therapeutics Inc.

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.85B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

More about BEAM

Track Paul Tudor Jones's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Account